英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

ozonic    
a. 臭氧的,臭氧般的,含臭氧的

臭氧的,臭氧般的,含臭氧的


请选择你想看的字典辞典：
单词字典翻译
ozonic查看　ozonic　在百度字典中的解释百度英翻中〔查看〕
ozonic查看　ozonic　在Google字典中的解释Google英翻中〔查看〕
ozonic查看　ozonic　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Libtayo (cemiplimab-rwlc) FDA Approval History - Drugs. com
    Libtayo (cemiplimab-rwlc) is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), and non-small cell lung cancer (NSCLC)
  • label - accessdata. fda. gov
    LIBTAYO (cemiplimab-rwlc) injection for intravenous use is a sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow solution with a pH of 6
  • FDA Approves Cemiplimab for Adjuvant Cutaneous Squamous Cell . . .
    The US FDA has approved the supplemental biologics license application (sBLA) for cemiplimab-rwlc (Libtayo) as adjuvant treatment in adults with high-risk cutaneous squamous cell carcinoma (CSCC) 1 The sBLA approval was based on an extensive review of data from the pivotal phase 3 C-POST study (NCT03969004) which demonstrated a statistically significant and clinically meaningful improvement
  • Libtayo® (cemiplimab-rwlc) Approved in the U. S. as First and . . .
    The FDA evaluated Libtayo under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions An additional regulatory application is also under review in the European Union, with a decision expected by the first half of 2026
  • FDA Approves Cemiplimab as Adjuvant Immunotherapy for High . . .
    Last week, Regeneron announced the U S Food and Drug Administration (FDA) approval of cemiplimab-rwlc (Libtayo) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC), particularly in those with a high risk of recurrence after surgery and radiation 1 The PD-1 inhibitor was evaluated under priority review
  • Covering Every FDA Oncology Approval From October 2025
    FDA Approves Libtayo for High-Risk Cutaneous Squamous Cell Carcinoma The FDA has approved Libtayo (cemiplimab-rwlc) for adjuvant treatment in adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation This approval was based on the C-POST trial, which included 415 patients at high risk of recurrence
  • Regeneron’s Libtayo FDA Approved as First Immunotherapy to . . .
    The FDA has approved a new use of PD-1 inhibitor Libtayo (cemiplimab-rwlc) as a treatment for cutaneous squamous cell carcinoma (CSCC) that has a high risk of recurring after it has been treated with surgery and radiation The approval makes Libtayo the first immunotherapy approved for use after surgery and radiation and may change how patients are treated earlier in their disease As a PD-1
  • FDA Approves Immunotherapy for Cutaneous Squamous-cell . . .
    THE FOOD AND DRUG ADMINISTRATION (FDA) approved the immunotherapy Libtayo (cemiplimab) for high-risk cutaneous squamous-cell carcinoma (CSCC), a common skin cancer type The Oct 8, 2025, approval was based on findings that people given Libtayo after surgery and radiation lived longer without their disease recurring—a measure known as disease-free survival—compared with those treated with
  • FDA Approves Cemiplimab (Libtayo) for Cutaneous Squamous Cell . . .
    The U S Food and Drug Administration approved adjuvant cemiplimab (Libtayo) for adults with cutaneous squamous cell carcinoma who are at a high risk for recurrence after surgery and radiation
  • FDA Approves Libtayo for Adjuvant Treatment of High-Risk CSCC
    Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo The Food and Drug Administration (FDA) has approved Libtayo ® (cemiplimab-rwlc) for the





中文字典-英文字典  2005-2009